Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Multinational, Randomised, Open-labelled, Parallel-group, Active-controlled Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency

NCT02382939 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02382939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02382939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Multinational, Randomised, Open-labelled, Parallel-group, Active-controlled Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
February 12, 2015
Completion date
January 4, 2016
Enrollment
92 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

adult growth hormone deficiency, growth hormone disorder